Neuroprotection in experimental stroke with targeted neurotrophins

NeuroRx

Volumn 2, Issue 1, 2005, Pages 120-128

  Wu, Dafang ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Blood brain barrier; Drug targeting; Ischemic stroke; Neuroprotection; Neurotrophins; Transferrin receptor

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; AVIDIN; BASIC FIBROBLAST GROWTH FACTOR; BIOTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; INSULIN RECEPTOR ANTIBODY; MACROGOL 2000; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX 26; NERVE GROWTH FACTOR; NEUROTROPHIN; PEPTIDE; PROUROKINASE; STREPTAVIDIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFERRIN; TRANSFERRIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

BIOTINYLATION; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CHIMERA; CLINICAL TRIAL; DOSE RESPONSE; DRUG CONJUGATION; DRUG TARGETING; HUMAN; IMMUNOGENICITY; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REACTION TIME; REVIEW; TREATMENT FAILURE;

EID: 12344336804     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.1.120     Document Type: Article

References (67)

1. Broderick JP. William M. Feinberg Lecture: stroke therapy in the year 2025. Burden, breakthroughs, and barriers to progress. Stroke 35:205-211, 2004.
2. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 91:311-322, 1989.
3. The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995.
4. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute ischemic cerebral thromboembolism. JAMA 282:2003-2011, 1999.
5. Ford GA, Bryant CA, Mangoni AA, Jackson SHD. Stroke, dementia, and drug delivery. Br J Clin Pharmacol 57:15-26, 2004.
6. Hacke W, Brott T, Caplan LR, Meier D, Fieschi C, von Kummer R, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53[Suppl]:S3-S14, 1999.
7. Hinkle JL, Bowman L. Neuroprotection for ischemic stroke. J Neurosci Nurs 35:114-118, 2003.
8. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 3:9-20, 2003.
9. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischemia: Facts and fancies - the need for new approaches. Cerebrovascular Dis 17[Suppl I]:153-166, 2004.
10. Menzies SA, Betz AL, Hoff JT. Contributions of ions and albumin to the formation and resolution of ischemic brain edema. J Neurosurg 78:257-266, 1993.
11. Keep RF. Editorial comment. Stroke 32:1381-1382, 2001.
12. Hefti F. Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol 37:239-267, 1997.
13. Hefti F, Hartikka JA, Montero CN, Junard EO. Role of nerve growth factor in the central nervous system. In: Neurobiology of amino acid, peptides, and trophic factors (Ferrendelli JA, Collins RC, Johnson EM, eds), pp 127-138. Norwell, MA: Kluwer Academic Publishers, 1988.
14. Levi-Montalcini R, Angeletti PU. Nerve growth factor. Physiol Rev 48:534-569, 1968.
15. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transactions. J Neurosci 6:2155-2162, 1986.
16. Will B, Hefti F. Behavioral and neurochemical effects of chronic intravenous injection of nerve growth factor in adult rats with fimbria lesions. Behav Brain Res 17:17-24, 1985.
17. William L, Varon S, Peterson G, Wictorin K, Bjorklund A, Gage F. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 33:9231-9235, 1986.
18. Shigeno T, Mima T, Takakura K, Graham DI, Kato G, et al. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J Neurosci 11:2914-2919, 1991.
19. Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, et al. Nerve growth factor affects C-11 nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm 4:79-95, 1992.
20. Pardridge WM. Peptide drug delivery to the brain. New York: Raven Press, 1-357, 1991.
21. Henderson CE, Camu W, Mettling C, Gouin A, Poulsen K, Karihaloo M, et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature 363:266-270, 1993.
22. Lindsay RM. Brain-derived neurotrophic factor: an NGF related neurotrophin. In: Neurotrophic factors (Fallon JH, Loughlin SE, eds), pp 257-284. New York: Academic Press, 1993.
23. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrests of motor neuron disease in Wobbler mice cotreated with CNTF and BDNF. Science 265:1107-1110, 1994.
24. Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature 360:753-755, 1992.
25. Tsukahara T, Yonekawa MD, Tanaka K, Ohara O, Watanabe S, et al. The role of brain-derived neurotrophic factor in transient forebrain ischemia in the rat brain. Neurosurgery 34:323, 1994.
26. Bradley WG. A phase I/II study of recombinant brain-derived neurotrophic factor in patients with ALS. Ann Neurol 38:971, 1995.
27. The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52:1427-1433, 1999.
28. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administrated by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:201-206, 2000.
29. Pardridge WM, Kang Y-S, Buciak JL. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharma Res 11:738-746, 1994.
30. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41, 1993.
31. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G. Hypotensive activity of fibroblast growth factor. Science 254:1208-1210, 1991.
32. Rosenblatt S, Irikura K, Caday CG, Finklestein SP, Moskowitz MA. Basic fibroblast growth factor dilates rat pial arterioles. J Cereb Blood Flow Metab 14:70-74, 1994.
33. Ay H, Ay I, Joroshetz WJ, Finklestein SP. Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovascular Dis 9:131-135, 1999.
34. Deguchi Y, Naito T, Yuga T, Furukawa A, Yamada S, Pardridge WM, et al. Blood-brain barrier transport of I-125 labeled fibroblast growth factor. Pharma Res 17:63-69, 2000.
35. The FIBLAST Safety Study Group. Clinical safety of intravenous bFGF in acute stroke. Stroke 29:287, 1998.
36. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, et al. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovas Dis 14:239-251, 2002.
37. Jeffries WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 312:162-163, 1984.
38. Pardridge WM. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol 513:397-430, 2002.
39. Wu D, Pardridge WM. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exper Ther 279:77-83, 1996.
40. Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA 96:254-259, 1999.
41. Wu D, Song B-W, Vinters HV, Pardridge WM. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target 10:239-245, 2002.
42. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor (BDNF) to a blood-brain barrier targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 889:49-56, 2001.
43. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32:1378-1384, 2001.
44. Said SI, Mutt V. Polypeptide with broad biological activity. Isolation from small intestine. Science 169:1217-1218, 1970.
45. Suzuki Y, McMaster D, Lederis K, Rorstad OP. Characterization of relaxant effects of vasoactive intestinal peptide (VIP) and PHI on isolated brain arteries. Brain Res 322:9-16, 1984.
46. Yaksh TL, Wang J-Y, Go VLW. Cortical vasodilatation produced by vasoactive intestinal peptide (VIP) and by physiological stimuli in the rat. J Cereb Blood Flow Metab 7:315-326, 1987.
47. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 97:2299-2307, 1996.
48. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, et al. Neuronal cell killing by the envelope protein HIV and its prevention by vasoactive intestinal peptide. Nature 335:639-642, 1988.
49. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, et al. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exper Ther 273: 161-167, 1995.
50. McCulloch J, Edvinsson L. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. Am J Physiol (Lond) 238:H449-H456, 1980.
51. Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM. Pharmacologic effects in vivo in brain by vector-mediated peptide delivery. Proc Natl Acad Sci USA 90:2618-2622, 1993.
52. Kang Y-S, Pardridge WM. Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J Pharmacol Exper Ther 269: 344-350, 1994.
53. Kang Y-S, Saito Y, Pardridge WM. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J Drug Target 3:159-165, 1995.
54. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharma Res 15:576-582, 1998.
55. Schabitz W-R, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 31:2212-2217, 2000.
56. Song B-W, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exper Ther 301:605-610, 2002.
57. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 324:14-30, 2002.
58. Shin SU, Wu D, Ramanathan R, Pardridge WM, Morrison SL. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol 158:4797-4804, 1997.
59. Pardridge WM. Brain drug targeting. The future of brain drug development. Cambridge, UK: Cambridge University Press, 2001.
60. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primary blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 100:1804-1812, 1997.
61. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17:266-274, 2000.
62. Ataus SA, Onal MZ, Ozdem SS, Locke KW, Balkan S. The effects of citicoline and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. Int J Neurosci. 114:183-196, 2004.
63. Bradberry JC, Fagan SC, Gray DR, Moon YS. New perspectives on the pharmacotherapy of ischemic stroke. J Am Pharm Assoc 44[2 Suppl 1]:S46-S56, 2004.
64. Chen SD, Lee JM, Yang DI, Nassief A, Hsu CY. Combination therapy for ischemic stroke: potential of neuroprotectants plus thrombolytics. Am J Cardiovasc Drugs 2:303-313, 2002.
65. Sobrado M, Lopez MG, Carceller F, Garcia AG, Roda JM. Combined nimodipine and citicoline reduce infarct size, attenuation apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 118:107-113, 2003.
66. Nappi J, Talbert R. Dual antiplatelet therapy for prevention of recurrent ischemic events. Am J Health Syst Pharm 59:1723-1735, 2002.
67. Schabitz WR, Li F, Irie K, Sandage BW Jr, Locke KW, Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 30:427-431, 1999.